Results 121 to 130 of about 2,264,000 (323)

Epigenetic Modification Mechanisms Involved in Inflammation and Fibrosis in Renal Pathology

Mediators of Inflammation, 2018
The growing incidence of obesity, hypertension, and diabetes, coupled with the aging of the population, is increasing the prevalence of renal diseases in our society. Chronic kidney disease (CKD) is characterized by persistent inflammation, fibrosis, and
J. L. Morgado-Pascual, Vanessa Marchant, Raúl R. Rodrigues-Díez, Nuria Doladé, B. Suarez-Alvarez, B. Kerr, J. Valdivielso, M. Ruíz-Ortega, S. Rayego‐Mateos   +8 more
semanticscholar   +1 more source

Genome-Wide Epigenetic Modifications in Cancer [PDF]

, 2010
Epigenetic alterations in cancer include changes in DNA methylation and associated histone modifications that influence the chromatin states and impact gene expression patterns. Due to recent technological advantages, the scientific community is now obtaining a better picture of the genome-wide epigenetic changes that occur in a cancer genome.
Park, Yoon Jung, Claus, Rainer, Weichenhan, Dieter, Plass, Christoph   +3 more
openaire   +2 more sources

ATF4‐mediated stress response as a therapeutic vulnerability in chordoma

Molecular Oncology, EarlyView.
We screened 5 chordoma cell lines against 100+ inhibitors of epigenetic and metabolic pathways and kinases and identified halofuginone, a tRNA synthetase inhibitor. Mechanistically halofuginone induces an integrated stress response, with eIF2alpha phosphorylation, activation of ATF4 and its target genes CHOP, ASNS, INHBE leading to cell death ...
Lucia Cottone, James Dunford, Eleanor Calcutt, Vicki Gamble, Filiz Senbabaoglu Aksu, Lorena Ligammari, Georgina Wherry, Giorgia Gaeta, John C. Christianson, Adrienne M. Flanagan, Udo Oppermann, Adam P. Cribbs   +11 more
wiley   +1 more source

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon, Peter T. Gallagher, Orly I. Richter, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer J. McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J. Paller, Wm. Kevin Kelly, Karen E. Knudsen, Matthew J. Schiewer, Ayesha A. Shafi   +13 more
wiley   +1 more source

Subtype‐specific enhancer RNAs define transcriptional regulators and prognosis in breast cancers

Molecular Oncology, EarlyView.
This study employed machine learning methodologies to perform the subtype‐specific classification of RNA‐seq data sets, which are mapped on enhancers from TCGA‐derived breast cancer patients. Their integration with gene expression (referred to as ProxCReAM eRNAs) and chromatin accessibility profiles has the potential to identify lineage‐specific and ...
Aamena Y. Patel, Peyman Zarrineh, Nathnael T. Tuffa, Jigar H. Sheth, Sumitra Mohan, Mudassar Iqbal, Sankari Nagarajan   +6 more
wiley   +1 more source

Epigenetics in ovarian cancer: premise, properties, and perspectives. [PDF]

, 2018
Malignant ovarian tumors bear the highest mortality rate among all gynecological cancers. Both late tumor diagnosis and tolerance to available chemical therapy increase patient mortality.
Huang, Shuang, Lau, Bonnie, Lau, Wayne Bond, Tang, Kexin, Wang, Hongjing, Wang, Wei, Wang, Xin, Wei, Yuquan, Xu, Lian, Yang, Qilian, Yang, Yuqing, Yang, Zhengnan, Yi, Tao, Zhao, Linjie, Zhao, Xia, Zhou, Nianxin, Zhou, Shengtao   +16 more
core   +2 more sources

Targeted modulation of IGFL2‐AS1 reveals its translational potential in cervical adenocarcinoma

Molecular Oncology, EarlyView.
Cervical adenocarcinoma patients face worse outcomes than squamous cell carcinoma counterparts despite similar treatment. The identification of IGFL2‐AS1's differential expression provides a molecular basis for distinguishing these histotypes, paving the way for personalized therapies and improved survival in vulnerable populations globally.
Ricardo Cesar Cintra, Lucca Paolo Hsu Helmich, Daniel Rodrigues de Bastos, Laura Sichero, Patrícia Savio de Araujo‐Souza, Fabio Passetti, Luisa Lina Villa   +6 more
wiley   +1 more source

Research progress and applications of epigenetic biomarkers in cancer

Frontiers in Pharmacology
Epigenetic changes are heritable changes in gene expression without changes in the nucleotide sequence of genes. Epigenetic changes play an important role in the development of cancer and in the process of malignancy metastasis.
Jianjun Gao, Wujiang Shi, Jiangang Wang, Canghai Guan, Qingfu Dong, Jialin Sheng, Xinlei Zou, Zhaoqiang Xu, Yifei Ge, Chengru Yang, Jiehan Li, Haolin Bao, Xiangyu Zhong, Yunfu Cui   +13 more
doaj   +1 more source

Extracting histones for the specific purpose of label-free MS [PDF]

, 2016
Extracting histones from cells is the first step in studies that aim to characterize histones and their post-translational modifications (hPTMs) with MS.
De Clerck, Laura, Deforce, Dieter, Dhaenens, Maarten, Govaert, Elisabeth, Meert, Paulien, Scheerlinck, Ellen, Stella, Martina, Van Steendam, Katleen, Vossaert, Liesbeth, Willems, Sander   +9 more
core   +2 more sources

RIPK4 function interferes with melanoma cell adhesion and metastasis

Molecular Oncology, EarlyView.
RIPK4 promotes melanoma growth and spread. RIPK4 levels increase as skin lesions progress to melanoma. CRISPR/Cas9‐mediated deletion of RIPK4 causes melanoma cells to form less compact spheroids, reduces their migratory and invasive abilities and limits tumour growth and dissemination in mouse models.
Norbert Wronski, Sławomir Lasota, Ewelina Madej, Anna A. Brożyna, Małgorzata Szczygieł, Agnieszka Harazin‐Lechowska, Jan Czerbniak, Janusz Rys, Jaroslaw Czyz, Agnieszka Wolnicka‐Glubisz   +9 more
wiley   +1 more source